Sutro Biopharma, Inc. (STRO)
| Market Cap | 918.30M |
| Revenue (ttm) | 42.72M |
| Net Income (ttm) | -32.13M |
| Shares Out | 32.57M |
| EPS (ttm) | -0.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 16 |
| Last Price | $20.01 |
| Previous Close | $21.35 |
| Change ($) | -1.34 |
| Change (%) | -6.28% |
| Day's Open | 21.17 |
| Day's Range | 19.16 - 20.99 |
| Day's Volume | 439,662 |
| 52-Week Range | 7.06 - 28.30 |
SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of pre...
SAN FRANCISCO, April 8, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein en...
SOUTH SAN FRANCISCO, Calif., March 22, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of pre...
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -164.29% and -32.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif., March 18, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of pre...
Sutro Biopharma (STRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of prec...
Sutro is a leader in CFPS and has major collaborations to prove it. Its early data is a lethal late line cancer is very promising.
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...
SOUTH SAN FRANCISCO, Calif., Dec. 8, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...
iBio (NYSE: IBIO) shares are trading lower on Tuesday after the company announced a common stock offering. iBio's main area of business is plant-based protein expression technologies for vaccines and th...
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...
One of the company's pipeline treatments shows encouraging results in ovarian cancer patients.
Sutro Biopharma (NASDAQ: STRO) shares are trading higher on Friday after the company announced interim data on its STRO-002 Phase 1 dose-escalation study for patients with ovarian cancer. Sutro Biopharm...
Sutro Biopharma (STRO) is on the rise Friday with heavy trading of STRO stock despite the company not announcing anything new today. The post Sutro Biopharma: 7 Things for STRO Stock Investors to Know A...
Sutro Biopharma Inc. (NASDAQ: STRO) made a huge gain to close out the week after the firm provided an update from its ongoing dose-escalation in its ovarian cancer trial.
SOUTH SAN FRANCISCO, Calif., Dec. 3, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of prec...
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of prec...
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, today announced that Chief Execu...
SOUTH SAN FRANCISCO, Calif., Nov. 5, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...
SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 /PRNewswire/ -- Sutro Biopharma, Inc.
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -1.69% and 7.66%, respectively, for the quarter ended June 2020.
Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Sutro Biopharma (NASDAQ: STRO) shares are trading lower on Thursday after Wells Fargo initiated coverage on the stock with an Overweight rating and an $18 price target.
SOUTH SAN FRANCISCO, Calif., June 22, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of prec...
SOUTH SAN FRANCISCO, Calif., June 9, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...
These four cancer therapeutics stocks are poised to experience long-term growth. An investment in any of these today could bring huge rewards.
SAN FRANCISCO, May 21, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein eng...
SOUTH SAN FRANCISCO, Calif., May 21, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of preci...
SOUTH SAN FRANCISCO, Calif., May 14, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietar...
Sutro Biopharma: Revenue-Generating Platform Positioned For Growth
As of late, it has definitely been a great time to be an investor Sutro Biopharma
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 16.88% and 21.22%, respectively, for the quarter ended December 2019.
Sutro Biopharma's Platform Technology Makes It A Promising Oncology Pick For 2020
About STRO
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate rec... [Read more...]
| Industry Biotechnology | IPO Date Sep 27, 2018 |
| CEO William Newell | Employees 191 |
| Stock Exchange NASDAQ | Ticker Symbol STRO |
Financial Performance
In 2020, STRO's revenue was $42.72 million, a decrease of -0.03% compared to the previous year's $42.74 million. Losses were -$32.13 million, -42.37% less than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for STRO stock is "Strong Buy." The 12-month stock price forecast is 31.83, which is an increase of 59.07% from the latest price.